Jasper Therapeutics Q2 EPS $(0.15), Inline
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics (NASDAQ:JSPR) reported Q2 losses of $(0.15) per share, in line with analyst consensus estimates. This represents a 48.28% increase over losses of $(0.29) per share from the same period last year.
August 11, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Jasper Therapeutics reported Q2 losses in line with analyst estimates, showing a significant improvement from last year.
Jasper Therapeutics' Q2 losses were in line with analyst estimates, which means there are no surprises for the market. However, the significant improvement from last year's losses could be seen as a positive sign, potentially leading to a neutral to positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100